PPARA and colitis: NAAA, a lysosomal enzyme that involves in degradation of endogenous lipids, including PEA, has recently been identified as a new therapeutic target for colitis.6 PEA is an anti-inflammatory compound that activates peroxisome proliferator-activated receptor-α-dependent (PPAR-α) and exhibit beneficial effects on inflammations.1,20 F96 is a NAAA inhibitor that selectively and potently inhibit NAAA, lead to anti-inflammatory effects in many different inflammation experimental models.7 We used undifferentiated Caco-2 cells to examine the toxicity where F96 did not show significant toxicity.